Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK2 | O60674 | 5/20 | 0.46 |
| ▸ | JAK1 | P23458 | 5/20 | 0.46 |
| ▸ | TYK2 | P29597 | 5/20 | 0.46 |
| ▸ | RET | P07949 | 14/20 | 0.41 |
| ▸ | MET | P08581 | 1/20 | 0.37 |
| ▸ | JAK3 | P52333 | 4/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25418939 | 0.88 | RET (0.41) | JAK2JAK1TYK2RETMET | |
| SCHEMBL23411018 | 0.75 | SIGMAR1 (0.50) | MET | |
| SCHEMBL19300148 | 0.74 | JAK2 (0.48) | JAK2JAK1TYK2RETJAK3 | |
| SCHEMBL25416909 | 0.73 | BTK (0.45) | JAK2JAK1TYK2RET | |
| SCHEMBL25415536 | 0.72 | RET (0.50) | RET | |
| SCHEMBL19253538 | 0.72 | JAK2 (0.47) | JAK2JAK1TYK2RETJAK3 | |
| SCHEMBL19253460 | 0.72 | JAK2 (0.47) | JAK2JAK1TYK2RETJAK3 | |
| SCHEMBL25192565 | 0.71 | PIM1 (0.45) | JAK2JAK1TYK2RETJAK3 | |
| SCHEMBL16799648 | 0.71 | HTR2C (0.51) | — | |
| SCHEMBL21872437 | 0.70 | JAK1 (0.62) | JAK2JAK1TYK2RETJAK3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250090524-A1 | BTK INHIBITORS | BIOGEN MA INC. | 2025-03-20 | — | — | US | disclosed |
| CN-118984829-A | BTK inhibitors | 渤健马萨诸塞州股份有限公司 | 2024-11-19 | — | — | CN | disclosed |
| EP-4430048-A1 | BTK INHIBITORS | Biogen MA Inc. (US) | 2024-09-18 | — | — | EP | disclosed |
| WO-2023086575-A1 | BTK INHIBITORS | BIOGEN MA INC. (US) | 2023-05-19 | — | — | WO | disclosed |
| WO-2023086575-A1 | BTK INHIBITORS | BIOGEN MA INC. (US) | 2023-05-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250090524-A1 | BTK INHIBITORS | BTK, SYK, LYN | JAK2 6/4885JAK1 7/4885TYK2 12/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.